The Puretech Health PLC (PRTC) share price climbed 5.16% after releasing its year-end update and outlook for 2024. The company shared an overview of the significant strides made in its Wholly Owned Programs and Founded Entities throughout 2023.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The company also announced the launch of two new Founded Entities and provided an update on its financial stability and operational plans. PureTech made considerable advancements in 2023, notably the triumphant LYT-300 clinical trial targeting acute anxiety in healthy individuals and promising initial results from ongoing studies of LYT-200 in solid tumours and acute myeloid leukaemia.
Additionally, PureTech Health secured a deal with Royalty Pharma that could reach up to $500 million, coupled with significant clinical and regulatory progress in various Wholly Owned Programs and Founded Entities.
In its commitment to growth, PureTech is intensifying its efforts to develop its wholly-owned pipeline, mainly focusing on pulmonary and rare diseases.
The company will retain specific Glyph™ intellectual properties. Anticipated milestones for 2024 include the awaited outcomes from the late-stage trial of LYT-100 for idiopathic pulmonary fibrosis (IPF), expected in the fourth quarter.
The firm Introduced Seaport Therapeutics, a new clinical-stage neuroscience entity. This subsidiary will propel specific central nervous system (CNS) programs and related Glyph intellectual properties forward.
The neuroscience pipeline is experiencing rapid expansion, thanks to the Glyph platform, with the introduction of a new therapeutic candidate, LYT-320, and the commencement of two clinical trials in 2024 (LYT-300 and LYT-310).
PureTech also launched Gallop Oncology, a new clinical-stage oncology entity. This entity will focus on developing LYT-200 and other intellectual properties related to galectin-9. Further results from ongoing leukaemia and solid tumour trials are anticipated in 2024.
The company boasts a robust financial position, with an estimated Consolidated Cash, Cash Equivalents, and Short-Term Investments totalling around $320 million at the year's end.
Daphne Zohar, Founder and CEO of PureTech, commented: “PureTech has had a particularly productive year. One of the advantages of the hub-and-spoke model we pioneered is that it has enabled us to build an exciting pipeline of new medicines poised for tremendous growth without diluting our shareholders in almost seven years. Our Founded Entities are a significant source of value to us, and we have generated over $800 million in non-dilutive proceeds to advance our pipeline and growth since 2020.”
Puretech Health share price.
The PureTech Health share price climbed 5.16% to trade at 160.9p from Tuesday’s closing price of 153.0p.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading stocks, forex, cryptos, and beyond. Dive in and test their capabilities with complimentary demo accounts today!
- eToro Top stock trading platform with 0% commission – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.